“Suicide” Bacteria Shows Promise in Targeting Colorectal Cancer Tumors
PARIS – Researchers have engineered a strain of Salmonella typhimurium bacteria designed to self-destruct within tumors, triggering a potent immune response that shows early promise in combating colorectal cancer, according to a new study. The breakthrough, detailed by scientists at[InstitutionName-[InstitutionName-[InstitutionName-[InstitutionName-not specified in source], offers a potential new avenue for cancer therapy by harnessing the body’s own immune system to target and destroy cancerous growths.
The innovative approach centers on mature tertiary lymphoid structures (MTLS),groups of specialized immune cells that naturally form near tumors. By introducing the modified Salmonella directly into tumors, researchers aim to stimulate these MTLS, amplifying the immune response and bolstering the body’s ability to fight cancer. This research builds on growing understanding of the interplay between the immune system and cancer progress, and could possibly offer a less invasive and more targeted treatment option than traditional methods.
the engineered bacteria,a weakened strain of Salmonella typhimurium,is programmed to self-destruct once it reaches a high density within the tumor. Upon disintegration, the bacteria release a protein called “light,” which acts as a powerful immune activator. Initial tests were conducted on two mouse models prone to colorectal cancer: one genetically predisposed to developing intestinal tumors and another where cancer was chemically induced.
Researchers observed meaningful changes in innate immune cells following the implantation of the “suicide” bacteria.While the results are encouraging, scientists caution that the mouse immune system and gut bacteria differ from those of humans, and further research is needed to determine the therapy’s efficacy and safety in human trials. Potential concerns include unpredictable interactions with the patient’s microbiota and the possibility of unintended infections or inflammation caused by the live bacteria.
Despite these limitations,the study represents a significant step forward in exploring novel cancer therapies. If successfully translated to humans, this approach could provide a new therapeutic viewpoint for patients battling colorectal cancer and potentially other forms of the disease.
